MedPath

Neuropeptides in the Humane Intra- og Extracerebral Circulation.

Not Applicable
Completed
Conditions
Healthy
Migraine
Registration Number
NCT00399633
Lead Sponsor
Danish Headache Center
Brief Summary

The study aim at examining whether Sumatriptan changes the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Detailed Description

The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system.

The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • healthy volunteers
  • 18-50 years,
  • 50-100 kg.
  • Fertile women must use birth control.
Exclusion Criteria
  • All primary types of headache
  • Daily intake of medicine except birth control
  • Pregnancy
  • Hypertension
  • Hypotension
  • other chronic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Blood concentration of vasoactive intestinal polypeptide (VIP),
calcitonin gene-related protein (CGRP), pituitary adenylate cyclase
activating peptide (PACAP,) and the prostanoids
6-keto-PGF1α, PGE2, PGD2 and PGF2α, sampled from different
venous catheters.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Danish Headache Center

🇩🇰

Glostrup, Copenhagen, Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath